Same Drug Class

Pembrolizumab vs Nivolumab

Overview

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are both PD-1 (programmed cell death protein 1) checkpoint inhibitors that block the PD-1/PD-L1 axis, releasing suppression of anti-tumor T-cell immunity. Both are landmark immunotherapy agents; their indication profiles are vast and partially overlapping, but differ in dosing schedules, companion diagnostic requirements, and specific combinations.

Mechanism of Action

Both are humanized IgG4 monoclonal antibodies that bind PD-1 on T cells, preventing its interaction with PD-L1 (expressed on tumor cells and APCs) and PD-L2. By blocking this inhibitory checkpoint, they unleash anti-tumor T-cell cytotoxicity.

Pharmacokinetics

Pembrolizumab: IV every 3 or 6 weeks, half-life ~26 days, non-linear PK at low doses but near-linear at therapeutic doses. Nivolumab: IV every 2, 4, or 6 weeks, half-life ~27 days.

Key Indications and FDA Approvals

Both have extensive indication lists across many tumor types. Pembrolizumab has a unique tumor-agnostic approval for any MMR-deficient or MSI-H solid tumor — the first histology-independent cancer approval by the FDA. Both are approved for melanoma, NSCLC, urothelial carcinoma, head and neck squamous cell carcinoma, and others.

Nivolumab is uniquely combined with ipilimumab (CTLA-4 inhibitor) in multiple tumor types (melanoma, NSCLC, mesothelioma, RCC, colorectal cancer MSI-H), giving it a broader combination regimen footprint.

Pembrolizumab typically requires PD-L1 expression testing (TPS ≥1% or ≥50% thresholds depending on indication) for certain approvals, while nivolumab + ipilimumab is approved for RCC regardless of PD-L1 expression.

Both cause irAEs: pneumonitis, colitis, hepatitis, endocrinopathies (thyroid dysfunction, adrenal insufficiency, diabetes mellitus), dermatitis. The irAE incidence and spectrum are broadly similar between PD-1 inhibitors.

Key Takeaways

  • Both anti-PD-1 antibodies with equivalent mechanism and broadly similar efficacy across tumor types
  • Pembrolizumab: tumor-agnostic MMR-d/MSI-H approval; dominant in pembrolizumab+chemotherapy regimens
  • Nivolumab: established dual checkpoint (nivo+ipi) combinations; unique indication set
  • Dosing: pembrolizumab q3w or q6w; nivolumab q2w, q4w, or q6w

Fazit

For most PD-1-eligible tumor types, pembrolizumab and nivolumab have similar efficacy as single agents. Pembrolizumab is preferred for PD-L1-high NSCLC and MSI-H/MMR-deficient tumors (unique tumor-agnostic indication). Nivolumab is preferred when dual checkpoint blockade with ipilimumab is indicated (melanoma, RCC, mesothelioma, MSI-H colorectal).